STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS
Total positions of BlackRock, Inc. and its funds subject to notification:
% of shares and voting rights (total of point A) | % of shares and voting rights through financial instruments (total of point B) | Total of both in % (points A + B) | Total number of shares and voting rights of issuer | |
Resulting situation on the date on which threshold was crossed or reached | Below 5% shares Below 5% voting rights | Below 5% shares Below 5% voting rights | Below 5% shares Below 5% voting rights | 141,134,278 shares 806,883,011 voting rights |
Position of previous notification (if applicable) | 5.07% shares Below 5% voting rights | 0.02% shares Below 5% voting rights | 5.10% shares Below 5% voting rights |
Notified details of the resulting situation on the date on which the threshold was crossed:
Point A: Shares and voting rights
Class/type of shares ISIN code | Number of shares and voting rights | % of shares and voting rights | ||
Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
FI0009014377 | Below 5% shares Below 5% voting rights | Below 5% shares Below 5% voting rights | ||
SUBTOTAL A | Below 5% shares Below 5% voting rights | Below 5% shares Below 5% voting rights |
Type of financial instrument | Expiration date | Exercise/ Conversion Period | Physical or cash settlement | Number of shares and voting rights | % of shares and voting rights |
Securities Lent | N/A | N/A | Physical | Below 5% shares Below 5% voting rights | Below 5% shares Below 5% voting rights |
CFD | N/A | N/A | Cash | Below 5% shares Below 5% voting rights | Below 5% shares Below 5% voting rights |
SUBTOTAL B | Below 5% shares Below 5% voting rights | Below 5% shares Below 5% voting rights |
President and CEO | SVP, Corporate Functions |
Contact person:
tel. +358 10 426 2721
Publisher:
Communications
Orionintie 1A, FI-02200 Espoo,
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to
© OMX, source